China Vitamin Industry
Report 2014-2017
China is the world's largest production base
of vitamins, with vitamin C and vitamin E as its most important products,
wherein vitamin C and related products account for more than 60% of its total
output and vitamin E takes up about 30%. Since 2009, influenced by the
sluggish external demand and declining prices, China's output of vitamin
products has been declining sharply. In 2013, the output of various types of
vitamin products in China was about 201,000 tons, down 7.4% YoY.
Browse Full Report With TOC: http://www.marketresearchreports.biz/analysis-details/china-vitamin-industry-report2014-2017
China is also the
world's largest export base of vitamins, mainly vitamin C, vitamin E and
pantothenic calcium. In 2013, China's export volume of vitamin C and vitamin E
accounted for 55.0% and 23.7% of total export volume over the same period. In
addition, the proportions of D or DL-pantothenic acid (i.e. vitamin B3 or B5)
have increased to 5.7%.
Chinese vitamin
producers fall into two types: large integrated pharmaceutical enterprises and
professional vitamin producers. In 2009-2013, large integrated pharmaceutical
enterprises such as North China Pharmaceutical Co.,Ltd and Northeast
Pharmaceutical Group Co.,Ltd mostly had heavy burden historically and
encountered operating difficulties and development obstacles, thus their ratio
of R & D investment in total revenue was less than 3%; while professional
vitamin producers like NHU, Kingdomway, and Brother Enterprises Holding kept
higher gross margins of their products, with R & D investment generally
accounting for more than 4% of revenue.
In recent years, the
global and Chinese vitamin market has been exhibiting a monopolistic
competition pattern. CSPC Pharmaceutical Group, North China Pharmaceutical,
Northeast Pharmaceutical, Aland (Jiangsu) Nutraceutical, Shandong Luwei
Pharmaceutical and other Chinese companies with production capacity of more
than 15,000 tons, are the major suppliers in the global VC market. Zhejiang
Medicine, NHU, and PKU Healthcare together shared about 50% of the global
total capacity of VE. NHU, Zhejiang Medicine and Kingdomway three companies
together accounted for 40%-50% of the global total capacity of VA.
Since the vitamin
industry has high technical barriers, the existing major producers have
already formed their own competitive advantages and the cost of quitting is
high. So it is estimated that in 2014-2017, the monopolistic competition
pattern in China vitamin industry will persist.
Table of Content
1 Overview of
Vitamins
1.1 Definition
1.2 Classification
1.3 Global Overview
2 Development of
China Vitamin Industry
2.1 Status Quo
2.2 Import and Export
2.2.1 Export
2.2.2 Import
2.3 Competition
Pattern
3 China Vitamin
Market Segments
3.1 VA
3.1.1 Development
Status
3.1.2 Import and
Export
3.1.3 Market Price
3.2 VB
3.2.1 D or
DL-Pantothenic Acid (Vitamin B3 or Vitamin B5)
|
Office:
United States
|
|
State Tower
90 State Street, Suite 700 Albany, NY 12207 United States |
No comments:
Post a Comment